Over the past 12‑18 months the Ophthalmic Silicone Oil industry trends have accelerated through a series of strategic moves. In March 2024, Alcon entered a global distribution partnership with Indian med‑tech firm Biosense, expanding access to its 5000‑cSt oil in emerging markets. The same year, Bausch + Lomb completed the acquisition of Swiss start‑up SiliconeVis, adding a next‑generation, low‑viscosity oil platform that promises faster retinal re‑attachment. July 2024 saw the launch of Roche Vision’s “ClearVision‑O” – a sterile, pre‑filled syringe designed for minimally invasive vitrectomy, which has already secured CE‑Mark clearance. Regulatory momentum continued as the European Medicines Agency (EMA) issued revised guidelines in September 2024, allowing extended shelf‑life testing for silicone oil products, a shift that is expected to reduce inventory costs. Meanwhile, venture capital funding surged; a $45 million Series B round led by HealthTech Capital enabled NeuroOptic to scale its proprietary polymer‑blending technology across three new facilities in the U.S. Collectively, these developments signal a move toward higher‑purity formulations, broader geographic reach, and tighter integration of supply‑chain partners.